Longitudinal CITE-Seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: evolution of leukemic and immune cells at relapse.

Sarah CadotCarine ValleMarie TosoliniFrederic PontLaetitia LargeaudCamille LaurentJean Jacques FournieLoic YsebaertAnne Quillet-Mary

Published in: Biomarker research (2020)

These results could open new alternative of therapeutic strategies for ibrutinib-refractory CLL patients, based on immunotherapy or targeting B leukemic cells themselves.

Keyphrases

chronic lymphocytic leukemia
end stage renal disease
acute myeloid leukemia
newly diagnosed
single cell
ejection fraction
induced apoptosis
chronic kidney disease
prognostic factors
peritoneal dialysis
cell cycle arrest
cross sectional
drug delivery